Menopause typically occurs in women around age 51. However, hormone related symptoms frequently present themselves during perimenopause, one to two years before the cessation of menstrual cycles. Women who have had surgical ovarian removal (oophorectomy, one type of surgical menopause) are considered menopausal regardless of age. Hormone replacement for women who undergo surgical menopause is necessary at any age to prevent heart disease and osteoporosis. (*)
Women who are in the perimenopausal state are candidates for BHRT, this may be the best time to consider treatment. (*)
The use of bio-identical hormone replacement therapy (BHRT), is highly effective for improving the quality of life in women suffering from acute menopausal symptoms:
BHRT can provide protection against cardiovascular disease, in women whom have been on BHRT within 10 years of menopause. BHRT can also reduce the risk of colon cancer, diabetes, osteoporosis, and is known to improve cholesterol and memory. (*)
Bio-identical hormones have been available and used in hormone treatments for decades. They can be customly compounded to match each patient’s unique needs and body chemistry, as opposed to the “one size fits all” approach used by the off-the-shelf hormones. Bio-Identical Hormone therapy requires appropriate testing, examination and discussion of symptoms with a healthcare practitioner. (*)
The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women.
* Individual Results May Vary & Are Not Guaranteed